Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 10/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20666279 | 0.90 | — | — | |
| SCHEMBL19704891 | 0.87 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL14547676 | 0.82 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL2985783 | 0.82 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL9906266 | 0.82 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL22548935 | 0.82 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL2986783 | 0.80 | CHRNB2 (0.59) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL23658084 | 0.77 | GABRA5 (0.43) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL7884824 | 0.77 | GABRA5 (0.43) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL20368646 | 0.77 | GABRA5 (0.43) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | CHRNB2 600/4885CHRNA4 655/4885CHRNA3 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.